QUOTE AND NEWS
Reuters  Mar 8  Comment 
(Acrescenta informação sobre a EDP, no 16º parágrafo)
Reuters  Mar 6  Comment 
* Galp prevê capex 1.000 ME em 2012, 60 pct 'Exploração & Produção'
Reuters  Mar 1  Comment 
* Lucro REN cresce 9,3 pct 2011 com aumento base activos e corte custos
Reuters  Feb 10  Comment 
(Acrescenta com citações do CEO da Galp e actualiza cotação do título)
Reuters  Feb 7  Comment 
(Acrescenta com informação sobre compra corretora Brasil)
Reuters  Nov 18  Comment 
* Venda dos 33,3 pct que da ENI na Galp é uma questão de tempo
Globe Newswire  Nov 14  Comment 
CHATSWORTH, Calif., Nov. 14, 2011 (GLOBE NEWSWIRE) -- Capstone Turbine Corporation (www.capstoneturbine.com) (Nasdaq:CPST), the world's leading clean technology manufacturer of microturbine energy systems, recently received the 2011 NOVA Award from
Reuters  Nov 11  Comment 
(Acrescenta comentários de analistas, gráficos e background. Actualiza cotação Galp)
Reuters  Oct 28  Comment 
* Lucro líq. ajust Galp cai 32 pct 3ro tri'11, abaixo esperado
Reuters  Sep 20  Comment 
* Remuneração 'deep shore' não compensa risco




RELATED WIKI ARTICLES
 
TOP CONTRIBUTORS

Headquartered in Chicago, Illinois, NovaMed, Inc. (NOVA), formerly NovaMed Eyecare, Inc., is an emerging healthcare services company engaged in the operation of ambulatory surgery centers (ASCs) and the provision of optical products and services to eye-care professionals. Founded in 1995 and floated in 1999, the company was originally a provider of physician practice management services to eye-care professionals, and later entered the Laser Vision Correction (LVC) market. Since 2001, the company's primary focus has been on the acquisition, development, and operation of ASCs in partnership with healthcare professionals. The company currently has ownership interests in 34 ASCs located in 18 states, with the majority located adjacent to or near the physicians' practices. Most of these ASCs are single-specialty ophthalmic surgical facilities, where eye-care professionals perform surgical procedures, primarily cataract and refractive surgery (laser vision correction). The company also has a nonexclusive supply agreement with Alcon Laboratories, Inc., which allows NOVA to procure and utilize excimer lasers and other equipment manufactured by Alcon. As a result, the company also provides excimer lasers and other services to eye-care professionals for their use in performing laser vision correction surgery under fixed-site laser agreements. In addition, NovaMed also owns and operates optical laboratories (manufacture and sale of corrective lenses and eyeglasses), an optical-products purchasing organization (eyeglass frames and contact lenses purchased from other manufacturers), and a marketing products and services business. In 2004, the two broad divisions of ASC and Product Sales represented 72% and 28% of total revenues, respectively.

Cost containment, driven by ongoing pressure from the third-party payors, has fueled significant growth of surgical procedures performed in outpatient settings. A key driver of the growth has been the strong physician and patient preference for non-hospital locations, which provide easy access to the frail and the elderly, as well as more control over scheduling for the healthcare professional. Ophthalmology is the largest single type of outpatient surgery, representing approximately 27% of all outpatient surgeries performed in 2000. We believe ASC industry fundamentals remain attractive given the increasing focus on conditions afflicting the elderly such as cataracts. We note that cataract surgery accounted for an estimated 2.7 million of surgical procedures performed in 2002. At the company level, NOVA's practice management expertise and excess ASC capacity provides an opportunity to expand into allied high-growth surgical specialty areas. For instance, these may include other specialty areas, such as orthopedics and podiatry. Typically, NOVA owns approximately 65% of the ASC with the healthcare professional owning the balance. Given that an ASC's principal revenue source is the "facility fee" charged for surgical procedures performed in the center, we believe NOVA's partnering with ophthalmologists aligns common goals to increase volume and productivity while reducing capital outlay for both parties.




References

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki